Literature DB >> 12639301

DNA sequences in cationic lipid:pDNA-mediated systemic toxicities.

Jennifer D Tousignant1, Hongmei Zhao, Nelson S Yew, Seng H Cheng, Simon J Eastman, Ronald K Scheule.   

Abstract

Systemic delivery of synthetic gene transfer vectors such as cationic lipid:plasmid DNA (pDNA) complexes elicits a range of acute physiologic responses, which in the context of therapeutic gene delivery represent dose-limiting toxicities. The most prominent responses are transient leukopenia, thrombocytopenia, serum transaminase elevations, and elevations of proinflammatory cytokines such as interferon-gamma (IFN-gamma), interleukin-12 (IL-12), and tumor necrosis factor-alpha (TNF-alpha). The unmethylated CpG sequences present in plasmid DNA have been implicated as a major cause of the robust cytokine response that follows systemic administration of cationic lipid:pDNA complexes. However, the factors causing the additional significant toxicities (leukopenia, thrombocytopenia, and serum transaminase elevations) recently shown to be associated with vector administration have not been defined. We show here that DNA sequences, such as immune stimulatory CpG sequences, play a significant role in inducing the additional acute toxicities associated with cationic lipid:pDNA complex administration. Importantly, while methylating these CpG sequences results in greatly reduced cytokine levels, this modification does not eliminate their ability to generate the other systemic toxicities. Examples of non-CpG DNA sequences that induce distinct toxicity profiles when administered systemically in the form of cationic lipid:DNA complexes are also identified. Taken together, these results imply that specific DNA sequences are responsible for a significant portion of the systemic toxicities observed after administration of cationic lipid:pDNA complexes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639301     DOI: 10.1089/10430340360535760

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  5 in total

1.  Delivery of calf thymus DNA to tumor by folate receptor targeted cationic liposomes.

Authors:  Hong Li; Longzhu Piao; Bo Yu; Bryant C Yung; Wenpeng Zhang; Peng G Wang; James L Lee; Robert J Lee
Journal:  Biomaterials       Date:  2011-06-12       Impact factor: 12.479

2.  Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration.

Authors:  Ryan Gene Soderquist; Evan M Sloane; Lisa C Loram; Jacqueline A Harrison; Ellen C Dengler; Scott M Johnson; Luke D Amer; Courtney S Young; Makenzie T Lewis; Stephen Poole; Matthew G Frank; Linda R Watkins; Erin D Milligan; Melissa J Mahoney
Journal:  Pharm Res       Date:  2010-03-12       Impact factor: 4.200

3.  Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.

Authors:  Yuhua Wang; Hsing-Hao Su; Yang Yang; Yunxia Hu; Lu Zhang; Pilar Blancafort; Leaf Huang
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

4.  Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response.

Authors:  Marie-Elise Bonnet; Patrick Erbacher; Anne-Laure Bolcato-Bellemin
Journal:  Pharm Res       Date:  2008-08-16       Impact factor: 4.200

5.  Plasmid CpG depletion improves degree and duration of tumor gene expression after intravenous administration of polyplexes.

Authors:  Holger K de Wolf; Nina Johansson; Anh-Thy Thong; Cor J Snel; Enrico Mastrobattista; Wim E Hennink; Gert Storm
Journal:  Pharm Res       Date:  2008-03-04       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.